EASD/ESC Symposium: The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials

Wednesday, 23 September 2020, 08:30 - 10:00, Linz Hall

Chair: D.R. Matthews, UK; A. Norhammar, SE

B. Zinman, CN: Evolution of clinical use of SGLT2i until EASD 2015, Stockholm

D.K. McGuire, US: Accumulated CV data from SGLT2i outcomes trials

N. Marx, DE: Mechanistic insights for CV benefits

C. Wanner, DE: Accumulated renal data from SGLT2i outcomes trials

D.Z. Cherney, CN: Mechanistic insights for renal benefits

S.E. Inzucchi, US: Implications for treatment guidelines and future directions